CellSource Co., Ltd. AI Stock Analysis
Want to see JP:4880 full AI Analyst Report?
CellSource Co., Ltd. (4880) AI Stock Analysis
CellSource Co., Ltd.
(TSE/TYO:4880)
The score is held up by strong financial resilience (low leverage) and ongoing positive cash generation, but is pressured by deteriorating profitability/ROE and a clearly bearish technical setup (price below key moving averages with negative MACD). A high P/E further limits upside unless earnings power improves materially.
CellSource Co., Ltd. (4880) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 5.60B
- Dividend Yield
- 1.78%
- Average Volume (3M)
- 67.80K
- Price to Earnings (P/E)
- 56.7
- Beta (1Y)
- 0.92
- Revenue Growth
- -9.94%
- EPS Growth
- ―
- Country
- Japan
- Employees
- 148
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
CellSource Co., Ltd. Business Overview & Revenue Model
Company Description
CellSource Co., Ltd. operates within both the regenerative medicine and consumer product sectors. Among its offerings is Signalift, an anti-aging solution. The company, which was established in 2015, is headquartered in Tokyo, Japan.
CellSource Co., Ltd. Financial Statement Overview
Summary
Financials are supported by a very conservative balance sheet (minimal debt, stable assets/equity) and consistently positive operating/free cash flow. However, operating performance has weakened materially: profitability and returns on equity fell sharply in 2024–2025, and cash-flow quality showed some near-term pressure in 2025.
Income Statement
56NeutralBalance Sheet
85Very PositiveCash Flow
62Positive| Breakdown | TTM | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 | Oct 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.67B | 3.71B | 4.36B | 4.51B | 4.27B | 2.92B |
| Gross Profit | 2.11B | 2.09B | 2.36B | 3.16B | 3.05B | 2.06B |
| EBITDA | 469.11M | 371.03M | 282.38M | 1.29B | 1.63B | 1.05B |
| Net Income | 70.68M | 10.66M | 237.94M | 923.14M | 1.02B | 651.40M |
Balance Sheet | ||||||
| Total Assets | 6.98B | 7.11B | 7.17B | 6.89B | 4.60B | 3.37B |
| Cash, Cash Equivalents and Short-Term Investments | 4.79B | 4.71B | 4.32B | 4.78B | 3.12B | 2.41B |
| Total Debt | 25.26M | 56.72M | 77.29M | 97.54M | 0 | 1.10M |
| Total Liabilities | 991.71M | 1.10B | 1.13B | 689.49M | 815.72M | 645.58M |
| Stockholders Equity | 5.99B | 6.02B | 6.04B | 6.20B | 3.79B | 2.72B |
Cash Flow | ||||||
| Free Cash Flow | 289.90M | 289.90M | 98.47M | 498.62M | 752.89M | 843.36M |
| Operating Cash Flow | 333.10M | 333.10M | 591.72M | 846.69M | 847.60M | 898.19M |
| Investing Cash Flow | -3.29M | -3.29M | -614.96M | -624.08M | -169.39M | -256.12M |
| Financing Cash Flow | 61.07M | 61.07M | -437.24M | 1.45B | 14.42M | 9.35M |
CellSource Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4880, the sentiment is Negative. The current price of 282.00 is below the 20-day moving average (MA) of 295.80, below the 50-day MA of 313.58, and below the 200-day MA of 348.90, indicating a bearish trend. The MACD of -10.06 indicates Positive momentum. The RSI at 39.50 is Neutral, neither overbought nor oversold. The STOCH value of 49.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4880.
CellSource Co., Ltd. Peers Comparison
Overall Rating
- JP:488057Neutral
JP:497845Neutral
JP:777442Neutral
JP:459339Underperform
JP:777639Underperform
JP:459938Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:4880 | 57Neutral | JPY 5.58B | 56.74 | ― | 1.78% | -9.94% | ― |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| JP:4978 | 45Neutral | JPY 11.65B | -25.06 | ― | ― | -8.23% | -48.10% |
| JP:7774 | 42Neutral | JPY 26.88B | -73.78 | ― | ― | 17.05% | 10.47% |
| JP:4593 | 39Underperform | JPY 31.99B | -13.76 | ― | ― | -51.55% | 52.19% |
| JP:7776 | 39Underperform | JPY 6.70B | -5.83 | ― | ― | -56.16% | 3.12% |
| JP:4599 | 38Underperform | JPY 7.46B | -3.94 | ― | ― | ― | 4.85% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4880 | CellSource Co., Ltd. | 282.00 | -215.00 | -43.26% | |
| JP:4593 | Healios KK | 228.00 | -223.00 | -49.45% | |
| JP:4599 | StemRIM Inc. | 117.00 | -161.00 | -57.91% | |
| JP:4978 | ReproCELL Inc. | 109.00 | -48.00 | -30.57% | |
| JP:7774 | Japan Tissue Engineering Co., Ltd. | 653.00 | 175.00 | 36.61% | |
| JP:7776 | CellSeed Inc. | 169.00 | -232.00 | -57.86% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026